Cleared Traditional

K152361 - OptiOne Single-Head Contrast Delivery S...

Also marketed or referenced as:
with Ceiling Suspension Injector, OptiOne Base System

K152361 is the FDA 510(k) clearance for OptiOne Single-Head Contrast Delivery S... by Liebel-Flarsheim Company, LLC. It is a Class 2 Cardiovascular device (product code IZQ) cleared through the Traditional 510(k) pathway after a 147-day FDA review.

K152361 · Liebel-Flarsheim Company, LLC · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jan 2016
Decision
147d
Days
Class 2
Risk

K152361 is an FDA 510(k) clearance for the OptiOne Single-Head Contrast Delivery System with Pedestal. Classified as Injector, Contrast Medium, Automatic (product code IZQ), Class II - Special Controls.

Submitted by Liebel-Flarsheim Company, LLC (Cincinnati, US). The FDA issued a Cleared decision on January 14, 2016 after a review of 147 days - within the typical 510(k) review window.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1650 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Liebel-Flarsheim Company, LLC devices

Submission Details

510(k) Number K152361 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 20, 2015
Decision Date January 14, 2016
Days to Decision 147 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
22d slower than avg
Panel avg: 125d · This submission: 147d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code IZQ Injector, Contrast Medium, Automatic
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1650
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - IZQ Injector, Contrast Medium, Automatic

All 13
Devices cleared under the same product code (IZQ) and FDA review panel - the closest regulatory comparables to K152361.
ulricheasyINJECT Max 2M (XD 10140)
K233737 · Ulrich GmbH & Co. KG · Apr 2024
ulrichINJECT CT motion
K210541 · Ulrich GmbH & Co. KG · Aug 2021
ulrichINJECT CT Motion
K192872 · Ulrich GmbH & Co. KG · Jul 2020
EMPOWERMR INJECTOR SYSTEM, MODEL 9730
K062449 · E-Z-Em, Inc. · Apr 2007
MEDRAD STELLANT CT INJECTOR SYSTEM WITH XDS ACCESSORY
K063090 · Medrad, Inc. · Mar 2007
EMPOWERCTA INJECTOR SYSTEM, MODELS 9930 & 9910 & 9825
K031571 · E-Z-Em, Inc. · Jun 2003